Abstracts tagged "dermatomyositis"

Abstract Number: 2070 • ACR Convergence 2025
Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
Pranathi Bandarupalli¹, Vineeth Potluri², Amr Alemairy², Harsharn Grewal² and Shudipan Chakraborthy², ¹Mercy St Vincent Medical Center, Toledo, OH, ²Mercy Health St. Vincent Medical Center, Toledo, OH
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), including polymyositis and dermatomyositis, are rare systemic autoimmune disorders characterized by chronic muscle inflammation and progressive muscle weakness. Patients with…
Abstract Number: 0864 • ACR Convergence 2025
Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
Danica Lee¹, Daniel Reay², Timothy Oriss², Didem Saygin³, Dana Ascherman⁴ and Daniella Schwartz⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Rush University Medical Center, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM), or myositis, comprise a group of autoimmune diseases with significant morbidity, yet the pathogenesis of myositis remains incompletely understood. In…
Abstract Number: 1741 • ACR Convergence 2025
Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin
Marianne Kerski¹, Celine Berthier¹, Benjamin Klein¹, Li Chen², Christine Goudsmit², Sophia Matossian¹, Qinmengge Li³, Chioma Madubata⁴, Jessica Neely⁵, J. Michelle Kahlenberg¹ and Jessica Turnier⁶, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ypsilanti, MI, ⁴UCSF, SF, CA, ⁵UCSF, San Francisco, CA, ⁶University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset SLE (cSLE) are systemic autoimmune diseases characterized by overlapping yet distinct clinical manifestations and treatment responses. In this study,…
Abstract Number: 2071 • ACR Convergence 2025
Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
valeria cantu¹, Rebeca L. Polina-Lugo¹, Emmanuel Dominguez-Chapa², Ana Cecilia Bardan Inchaustegui³, Fernanda M. Garcia-Carrillo⁴, Daniela A. Mejia-Rodriguez⁴, Ericka S. Reyna-Hernandez⁴, Rosa Arvizu-Rivera⁵, Jesus Alberto Cardenas-de la Garza⁶ and Miguel Villarreal-Alarcón⁷, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Hospital Universitario UANL, Monterrey, Nuevo León, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of autoimmune diseases marked by inflammation of muscle tissue and extramuscular manifestations. Their atypical…
Abstract Number: 0865 • ACR Convergence 2025
Spatial Transcriptomic Analysis of Calcinosis Cutis in Dermatomyositis Uncovers Disease-Associated Pathways Involving IL-6, Tissue Remodeling, and Osteopontin
Cassie Parks¹, York Wang¹, Lisa Christopher-Stine², Jemima Albayda², Joel Sunshine³, Shira Ziegler¹ and Chris Mecoli¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Calcinosis cutis affects up to 20% of adults with dermatomyositis (DM), causing significant morbidity including recurrent infections, incapacitating pain, and functional impairment. Current management…
Abstract Number: 1745 • ACR Convergence 2025
High Emotional Distress Predicts Suboptimal Cardiovascular Health Among Patients with Juvenile-Onset Lupus and Dermatomyositis: Longitudinal Analysis of the Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Kaveh Ardalan¹, Angel Davalos¹, Hwanhee Hong¹, Bryce Reeve¹, Christoph Hornik¹, M. Anthony Moody¹, Donald Lloyd-Jones², Eveline Wu³, Audrey Ward⁴, Simisola Gbadegesin⁵, Rebecca Sadun⁶, Jeffrey Dvergsten⁷, Lauren Covert¹, Ann Reed¹, Mark Connelly⁸ and Laura Schanberg⁹, ¹Duke University School of Medicine, Durham, NC, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³UNC Chapel Hill, Chapel Hill, NC, ⁴Children's National Hospital, Washington, DC, ⁵Wake Forest University School of Medicine, Winston-Salem, NC, ⁶Duke University, Durham, NC, ⁷Duke University Hospital, Hillsborough, NC, ⁸Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁹Duke University Medical Center, DURHAM, NC
Background/Purpose: Juvenile lupus & dermatomyositis (JSLE/JDM) patients experience high emotional distress and premature loss of cardiovascular health (CVH), defined as protective factors against cardiovascular disease…
Abstract Number: 2074 • ACR Convergence 2025
Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
Sergio Maldonado Chaar¹ and Kelly Corbitt², ¹University of Miami/Jackson Health, Miami, FL, ²University of Miami Miller School of Medicine, El Portal, FL
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA-5) antibody positivity in dermatomyositis (DM) is often associated with development of interstitial lung disease (ILD), with factors such as…
Abstract Number: 0653 • ACR Convergence 2025
In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens
May-Linda Lepage¹, Patrick Nolain¹, Céline Cottereaux¹, Emilie Lagoutte¹, Justine Dao¹, Adrien Cosson¹, Laetitia Furio¹, Willem Hettema², Chantal Tasset³, Roland Blanqué¹, Isabelle Parent¹ and René Galien¹, ¹Galapagos SASU, Paris, France, ²Galapagos B.V., Leiden, Netherlands, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with…
Abstract Number: 1770 • ACR Convergence 2025
Brepocitinib Inhibits Key Pathogenic Cytokine Signaling in Dermatomyositis Patients
Christina Charles-Schoeman¹, Yessar Hussain² and Brendan Johnson³, ¹UCLA Medical Center, Santa Monica, CA, ²Austin Neuromuscular Center, Austin, TX, ³Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease of the skin and muscles with significant unmet need and limited treatment options. Brepocitinib is an oral,…
Abstract Number: 2076 • ACR Convergence 2025
Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions
Latika Gupta¹, Taanya Talreja² and Peter Kerkhof³, ¹School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ²KEM Hospital, Mumbai, Maharashtra, India, ³Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Background/Purpose: The intersection of nutrition and autoimmune myopathies represents a significant yet understudied domain in rheumatological care. We conducted a meticulous analysis of online myositis…
Abstract Number: 0026 • ACR Convergence 2025
Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis
Bilgesu Safak Tümerdem¹, Yi-Nan Li², Tim Filla³, Rolf Schröder⁴, Anna Brunn⁵, Alexandru Micu⁶, Ayla Nadja Stuetz¹, Laura-Marie Lahu⁶, Aleix Rius Rigau⁷, Christina Bergmann⁸, Alexandru-Emil Matei⁹, Jörg Distler¹⁰ and Andrea-Hermina Györfi¹¹, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital of Düsseldorf, Düsseldorf, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴Institute of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Institute of Neuropathology, Heinrich-Heine University, University Hospital of Düsseldorf, Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁷Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Immune-mediated inflammatory myopathies (IIMs) are a heterogeneous group of diseases characterized by chronic inflammation, damage and impaired regeneration of the skeletal muscle leading to…
Abstract Number: 0916 • ACR Convergence 2025
UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway
Ahmed Eldaboush¹, Darae Kang² and Victoria Werth³, ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Potomac, MD, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) are cell-derived nanoparticles that mediate cell-cell communication. EVs are implicated in photosensitive autoimmune diseases like dermatomyositis (DM) and systemic lupus (SLE),…
Abstract Number: 1816 • ACR Convergence 2025
Single-Cell RNA-Transcriptomics of JDM Skin Identifies JDM-Associated Immune Cell Populations and Dysregulated Interferon Signaling in Immune and Endothelial Cells
Chioma Madubata¹, Jessica Neely², Christine Goudsmit³, Celine Berthier⁴, Zilan Zheng⁵, Sophia Matossian⁴, Jeffrey Dvergsten⁶, Andrew Heaton⁷, J. Michelle Kahlenberg⁴, Gabrielle Fragiadakis⁸ and Jessica Turnier⁹, ¹UCSF, SF, CA, ²UCSF, San Francisco, CA, ³University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, MI, ⁵University of California, San Francisco, San Francisco, CA, ⁶Duke University Hospital, Hillsborough, NC, ⁷Cure JM Foundation, Anthony, FL, ⁸UCSF, San Francisco, ⁹University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. JDM often presents with rash, and skin inflammation is more refractory to…
Abstract Number: 2131 • ACR Convergence 2025
Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype
Austen Grooms¹, Ioannis Karageorgiou², Kerry Mychaliska² and James Birmingham³, ¹William Beaumont University Hospital, Auburn Hills, MI, ²William Beaumont University Hospital, Royal Oak, MI, ³River City Rheumatology, Grand Rapids, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…
Abstract Number: 1007 • ACR Convergence 2024
Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].